PRF Technologies Ltd. · NASDAQ:PRFX
PRF Technologies — PainReform — IPO Roadshow (August 2020)
19 slides from PRF Technologies's IPO roadshow presentation, August 2020
Slide 1: Investor Presentation: Initial Public Offering
Investor Presentation Initial Public Offering August 2020
Slide 2: Important Notices
Important Notices Confidential Information This presentation and the information contained in this presentation are confidential and proprietary and are being given to you on a confidential basis. No part of this presentation or the information contained herein may be reproduced, photocopied, redist
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, anal
Slide 4: PRF-110 Executive Summary
PRF-110 Executive Summary ▪ Post-operative pain treatment is a growing market ($12B) with a need for better therapeutics1 o Local anesthetics provide pain relief for up to 6 hours and require augmentation with NSAIDs or opioids for moderate to severe pain, leading to side effects and dependence o Op
Slide 5: Investment Highlights
Investment Highlights 1 2 3 4 5 Innovative Opioid Epidemic Seasoned Robust US and Core platform Formulation / Presents Management International can be utilized Delivery System Significant Team with IP Portfolio for wide-range Commercial Decades of of APIs to Opportunity Experience generate sustainab
Slide 6: Management Team
Management Team Ehud Geller, PhD, MBA. Acting Chairman ▪ Former President & CEO of Interpharm Laboratories and EVP of Teva Group ▪ Former head of the Israeli Pharmaceutical Manufacturers Association and board member of the Tel Aviv Stock Exchange ▪ National Industry award for contribution to biotech
Slide 7: Management Team
Management Team Ehud Geller, PhD, MBA. Acting Chairman Eli Hazum, PhD, MBA. Chief Technical Officer David E. Weinstein, MD, PhD. Chief Medical Officer Sigal Aviel, PhD, MBA. Chief Operating Officer 7 PainReform Ltd.| www.painreform.com Post Operative Pain Management
Slide 8: Post-Operative Pain Management Market Overview
Post-Operative Pain Management Market Overview ▪ The 2017 world-wide overall post-operative pain treatment market was estimated at US$12B and is expected to reach in excess of US$45B by the end of 20261 4 ▪ Significant unmet need for long-acting local anesthetic agents in order to spare opioids use,
Slide 9: Problem: State of Opioid Crisis in America
Problem: State of Opioid Crisis in America ▪ 99% of surgical patients receive opioids to manage post-surgical pain1 ▪ Opioids dependency can start within 3 days of initial use 11.4 Million 2.1 Million People misused opioids in 2019. 886K People have an opioid use disorder. 1.7 ▪ 6% to 10% of surgica
Slide 10: Current Approaches in Post-Operative Analgesia Are Lacking
Current Approaches in Post-Operative Analgesia Are Lacking Short Acting Opioids Long Acting Opioids ▪ Repeated dosing required ▪ Poor efficacy in acute pain control ▪ Inconsistent pain control between doses ▪ Not intended for the treatment of post-operative pain ▪ Dependence risk increases with trea
Slide 11: PainReform Solution: PRF-110 Post Operative Pain Management
PainReform Solution: PRF-110 Post Operative Pain Management ▪ PainReform has developed a platform formulation for extended release of drugs ▪ Low COGS compared to current drug landscape1 Pain Reduction Time Scalable and Cost Effective Studies have shown 48 hours of pain Low variable costs allows for
Slide 12: PRF-110: Timeline to NDA
PRF-110: Timeline to NDA Historical Future (post Funding) FDA determined Initiate simultaneous double the CMC data Positive Phase 2, proof- blind, 3-arm (PRF-110:active adequate to of-concept study in comparator: placebo), placebo NDA submission ~22 proceed to Phase I hernia repair: pain controlled
Slide 13: Product differentiation PRF-110 vs. Competition
Product differentiation PRF-110 vs. Competition Pacira1 – Exparel™ Heron2-HTX 011 PRF-110 PRF-110 Advantages Watery, complex liposomal Biochronomer technology(4): Non- Waterless, viscous, oil-based Formulation Uniformity, viscosity, & retention suspension dilutable (Limited market) solution (GRAS) P
Slide 14: PRF-110 Safety
PRF-110 Safety ▪ PainReform carried out extensive FDA requested wound healing and related animal studies that showed: ✓ PRF-110 allows for normal wound healing of surgical incisions equal to both Naropin® and saline without any untoward histological or radiologic (microCT) effects observed in soft o
Slide 15: PRF-110 Phase 2 Results in Hernia
PRF-110 Phase 2 Results in Hernia PRF-110 Pain Reduction Up to 72-Hours After a Single Application 8 ▪ Efficacy PBO ➢ PRF-110 provided post- 7 Historical placebo data operative pain control for up Mean Pain Score 6 to 72 hours after a single PRF-110 Scale 1-10 application 5 4 ▪ Safety ➢ PRF-110 was
Slide 16: PRF-110: Phase III Clinical Trial Protocol
PRF-110: Phase III Clinical Trial Protocol ▪ Two, double blind, placebo control 72-hour treatment period, studies planned (bunionectomy and hernia repair). For each study: ▪ Three cohorts (n= ~400): 1. PRF-110; 2. Naropin® (ropivacaine); placebo; in a 2:2:1 ratio ▪ Primary endpoint (Efficacy) − Mean
Slide 17: PRF-110: Potential Best-In-Class
PRF-110: Potential Best-In-Class Efficacy Safety Cross study comparison of Phase II Met FDA required extensive pre-clinical studies data, 72 hours pain AUC to demonstrate no wound healing issues Administration COGS Low cost of good sold allows a highly PRF-110 viscosity and uniformity are highly str
Slide 18: Investment Highlights
Investment Highlights 1 2 3 4 5 Innovative Opioid Epidemic Seasoned Robust US and Core platform Formulation / Presents Management International can be utilized Delivery System Significant Team with IP Portfolio for wide-range Commercial Decades of of APIs to Opportunity Experience generate sustainab
Slide 19: Thank You
Thank You